

Table S2. Tumors used for quantitative reverse transcription PCR analysis and microarray analysis.

	Latency (wks)*	Histopathology	ER/PR
LFD	31	Cribriform carcinoma	ER-/PR-
	31	Papillary carcinoma	ER+/PR+
	34	Adenosquamous carcinoma	ER-/PR-
	39	Glandular carcinoma	ER+/PR+
HFD (early)	17	Ductal Carcinoma	ER+/PR+
	14	Adenosquamous/Cribriform CA	ER-/PR-
	10	Adenosquamous carcinoma	ER-/PR-
	10	Adenosquamous carcinoma	ER-/PR-
HFD (late)	29	Papillary carcinoma	ER+/PR+
	34	Papillary carcinoma	ER+/PR+
	35	Adenosquamous carcinoma	ER-/PR-
	45	Glandular carcinoma	ER+/PR+
LFD-HFD	28	Papillary carcinoma	ER-/PR-
	31	Glandular carcinoma	ER+/PR+
	37	Glandular carcinoma	ER+/PR+
	42	Glandular carcinoma	ER+/PR+
HFD-LFD (early)	10	Adenosquamous carcinoma	ER-/PR-
	16	Adenosquamous carcinoma	ER-/PR-
	17	Adenosquamous carcinoma	ER-/PR-
	19	Cribriform carcinoma	ER-/PR-
HFD-LFD (late)	26	Papillary carcinoma	ER-/PR-
	33	Glandular carcinoma	ER+/PR+
	38	Adenosquamous carcinoma	ER-/PR-

*Latency is presented as weeks post first DMBA treatment